Fc gamma receptors and cancer

Springer Seminars in Immunopathology

Volumn 28, Issue 4, 2006, Pages 321-328

  Cassard, Lydie ^a,c   Cohen Solal, Joël ^a,d   Camilleri Broët, Sophie ^a,b   Fournier, Emilie ^a   Fridman, Wolf Herman ^a   Sautès Fridman, Catherine ^a  

^a INSERM   (France)

^b HÔTEL DIEU   (France)

^c NATIONAL CANCER INSTITUTE   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Anti tumor immunity; Antibody therapy; B cell lymphoma; Melanoma; Prognostic value

Indexed keywords

FC GAMMA RECEPTOR I; FC GAMMA RECEPTOR IIB; FC RECEPTOR; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL IMMUNOGLOBULIN G ANTIBODY; ANTIGEN ANTIBODY COMPLEX; IMMUNOGLOBULIN G;

ANTIGEN PRESENTATION; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CYTOTOXICITY; DENDRITIC CELL; EFFECTOR CELL; IMMUNE RESPONSE; IMMUNITY; MACROPHAGE; MELANOMA; MONOCYTE; NATURAL KILLER CELL; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR IMMUNITY; ANTIGEN ANTIBODY COMPLEX; HUMAN; IMMUNOLOGY; METABOLISM;

ANTIGEN-ANTIBODY COMPLEX; DENDRITIC CELLS; HUMANS; IMMUNOGLOBULIN G; LYMPHOMA, B-CELL; MACROPHAGES; RECEPTORS, FC; RECEPTORS, IGG;

EID: 33845387434     PISSN: 03444325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00281-006-0058-8     Document Type: Review

References (74)

1. Hulett MD, Hogarth PM (1994) Molecular basis of Fc receptor function. Adv Immunol 57:1-127
2. Fridman WH, Bonnerot C, Daeron M, Amigorena S, Teillaud JL, Sautes C (1992) Structural bases of Fc gamma receptor functions. Immunol Rev 125:49-76
3. Takai T (2005) Fc receptors and their role in immune regulation and autoimmunity. J Clin Immunol 25:1-18
4. Deo YM, Graziano RF, Repp R, van de Winkel JG (1997) Clinical significance of IgG Fc receptors and Fc gamma R-directed immunotherapies. Immunol Today 18:127-135
5. Amigorena S, Bonnerot C, Drake JR, Choquet D, Hunziker W, Guillet JG, Webster P, Sautes C, Mellman I, Fridman WH (1992) Cytoplasmic domain heterogeneity and functions of IgG Fc receptors in B lymphocytes. Science 256:1808-1812
6. Van den Herik-Oudijk IE, Capel PJ, van der Bruggen T, van de Winkel JG (1995) Identification of signaling motifs within human Fc gamma RIIa and Fc gamma RIIb isoforms. Blood 85:2202-2211
7. Daeron M (1997) Fc receptor biology. Annu Rev Immunol 15:203-234
8. Sarmay G, Koncz G, Gergely J (1996) Integration of activatory and inhibitory signals in human B-cells. Immunol Lett 54:93-100
9. Isnardi I, Bruhns P, Bismuth G, Fridman WH, Daeron M (2006) The SH2 domain-containing inositol 5-phosphatase SHIP1 is recruited to the intracytoplasmic domain of human FcgammaRIIB and is mandatory for negative regulation of B cell activation. Immunol Lett 104:156-165
10. Sahin U, Tureci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I, Pfreundschuh M (1995) Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A 92:11810-11813
11. Jager E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jager D, Arand M, Wada H, Noguchi Y, Stockert E, Old LJ, Knuth A (1998) Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 187:265-270
12. Lake DF, Huynh WC, Hersh EM (2000) Natural and induced human antibody response to cancer. Cancer Invest 18:480-489
13. Ragupathi G, Meyers M, Adluri S, Howard L, Musselli C, Livingston PO (2000) Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21. Int J Cancer 85:659-666
14. Lutzky J, Gonzalez-Angulo AM, Orzano JA (2002) Antibody-based vaccines for the treatment of melanoma. Semin Oncol 29:462-470
15. Ehlken H, Schadendorf D, Eichmuller S (2004) Humoral immune response against melanoma antigens induced by vaccination with cytokine gene-modified autologous tumor cells. Int J Cancer 108:307-313
16. White CA, Weaver RL, Grillo-Lopez AJ (2001) Antibody-targeted immunotherapy for treatment of malignancy. Annu Rev Med 52:125-145
17. Carter PJ (2006) Potent antibody therapeutics by design. Nat Rev Immunol 6:343-357
18. Akiyama K, Ebihara S, Yada A, Matsumura K, Aiba S, Nukiwa T, Takai T (2003) Targeting apoptotic tumor cells to Fc gamma R provides efficient and versatile vaccination against tumors by dendritic cells. J Immunol 170:1641-1648
19. Rafiq K, Bergtold A, Clynes R (2002) Immune complex-mediated antigen presentation induces tumor immunity. J Clin Invest 110:71-79
20. Adams DO, Hall T, Steplewski Z, Koprowski H (1984) Tumors undergoing rejection induced by monoclonal antibodies of the IgG2a isotype contain increased numbers of macrophages activated for a distinctive form of antibody-dependent cytolysis. Proc Natl Acad Sci U S A 81:3506-3510
21. Denkers EY, Badger CC, Ledbetter JA, Bernstein ID (1985) Influence of antibody isotype on passive serotherapy of lymphoma. J Immunol 135:2183-2186
22. Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, Levy R (1994) Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84:2457-2466
23. Dyer MJ, Hale G, Hayhoe FG, Waldmann H (1989) Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 73:1431-1439
24. Clynes R, Takechi Y, Moroi Y, Houghton A, Ravetch JV (1998) Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci U S A 95:652-656
25. Bevaart L, Jansen MJ, van Vugt MJ, Verbeek JS, van de Winkel JG, Leusen JH (2006) The high-affinity IgG receptor, FcgammaRI, plays a central role in antibody therapy of experimental melanoma. Cancer Res 66:1261-1264
26. Nimmerjahn F, Ravetch JV (2005) Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310:1510-1512
27. Nimmerjahn F, Ravetch JV (2006) Fcgamma receptors: old friends and new family members. Immunity 24:19-28
28. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99:754-758
29. Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6:443-446
30. van Spriel AB, van Ojik HH, van de Winkel JG (2000) Immunotherapeutic perspective for bispecific antibodies. Immunol Today 21:391-397
31. Berends D, van der Kwast TH, de Both NJ, Mulder PG (1989) Factors influencing antibody-mediated cytotoxicity during the immunotherapy of Rauscher-virus-induced myeloid leukemic cells. Cancer Immunol Immunother 28:123-130
32. van Spriel AB, van Ojik HH, Bakker A, Jansen MJ, van de Winkel JG (2003) Mac-1 (CD11b/CD18) is crucial for effective Fc receptor-mediated immunity to melanoma. Blood 101:253-258
33. Sedmak DD, Davis DH, Singh U, van de Winkel JG, Anderson CL (1991) Expression of IgG Fc receptor antigens in placenta and on endothelial cells in humans. An immunohistochemical study. Am J Pathol 138:175-181
34. Lyden TW, Robinson JM, Tridandapani S, Teillaud JL, Garber SA, Osborne JM, Frey J, Budde P, Anderson CL (2001) The Fc receptor for IgG expressed in the villus endothelium of human placenta is Fc gamma RIIb2. J Immunol 166:3882-3889
35. Hussain LA, Kelly CG, Hecht EM, Fellowes R, Jourdan M, Lehner T (1991) The expression of Fc receptors for immunoglobulin G in human rectal epithelium. AIDS 5:1089-1094
36. Estienne V, Duthoit C, Reichert M, Praetor A, Carayon P, Hunziker W, Ruf J (2002) Androgen-dependent expression of FcgammaRIIB2 by thyrocytes from patients with autoimmune Graves' disease: a possible molecular clue for sex dependence of autoimmune disease. FASEB J 16:1087-1092
37. Milgrom F, Humphrey LJ, Tonder O, Yasuda J, Witebsky E (1968) Antibody-mediated hemadsorption by tumor tissues. Int Arch Allergy Appl Immunol 33:478-492
38. Tonder O, Thunold S (1973) Receptors for immunoglobulin Fc in human malignant tissues. Scand J Immunol 2:207-215
39. Witz IP (1973) The biological significance of tumor-bound immunoglobulins. Curr Top Microbiol Immunol 61:151-171
40. Biran H, Mavligit GM, Moake JL (1979) Receptor sites for complement and for immune complexes on human nonhemopoietic tumor cells. Cancer 44:131-135
41. Noltenius HW (1981) Fc and complement receptors on malignant tumor cells. Cancer 48:1761-1767
42. Braslawsky GR, Serban D, Witz IP (1976) Receptors for immune complexes on cells within a polyoma virus-induced murine sarcoma. Eur J Immunol 6:579-583
43. Svennevig JL, Andersson TR (1982) Cells bearing Fc receptors in human malignant solid tumours. Br J Cancer 45:201-208
44. Ran M, Teillaud JL, Fridman WH, Frenkel H, Halachmi E, Katz B, Gips M, Shlomo Y, Barzilay J, Witz IP (1988) Increased expression of Fc gamma receptor in cancer patients and tumor bearing mice. Mol Immunol 25:1159-1167
45. Ran M, Katz B, Kimchi N, Halachmi E, Teillaud JL, Even J, Berko-Flint Y, Atlas E, Fridman WH, Witz IP (1991) In vivo acquisition of Fc gamma RII expression on polyoma virus-transformed cells derived from tumors of long latency. Cancer Res 51:612-618
46. Szymaniec S, James K (1976) Studies on the Fc receptor bearing cells in a transplanted methylcholanthrene induced mouse fibrosarcoma. Br J Cancer 33:36-50
47. Gorini G, Ciotti MT, Starace G, Vigneti E, Raschella G (1992) Fc gamma receptors are expressed on human neuroblastoma cell lines: lack of correlation with N-myc oncogene activity. Int J Neurosci 62:287-297
48. Cassard L, Cohen-Solal JF, Galinha A, Sastre-Garau X, Mathiot C, Galon J, Dorval T, Bernheim A, Fridman WH, Sautes-Fridman C (2002) Modulation of tumor growth by inhibitory Fc(gamma) receptor expressed by human melanoma cells. J Clin Invest 110:1549-1557
49. Neauport-Sautes C, Daeron M, Teillaud JL, Blank U, Fridman WH (1986) The occurrence, structural and functional properties of immunoglobulin Fc receptors on murine neoplastic cells. Int Rev Immunol 1:237-271
50. Tridandapani S, Siefker K, Teillaud JL, Carter JE, Wewers MD, Anderson CL (2002) Regulated expression and inhibitory function of Fcgamma RIIb in human monocytic cells. J Biol Chem 277:5082-5089
51. Langer AB, Emmanuel N, Even J, Fridman WH, Gohar O, Gonen B, Katz BZ, Ran M, Smorodinsky NI, Witz IP (1992) Phenotypic properties of 3T3 cells transformed in vitro with polyoma virus and passaged once in syngeneic animals. Immunobiology 185:281-291
52. Zusman T, Lisansky E, Arons E, Anavi R, Bonnerot C, Sautes C, Fridman WH, Witz IP, Ran M (1996) Contribution of the intracellular domain of murine Fc-gamma receptor type IIB1 to its tumor-enhancing potential. Int J Cancer 68:219-227
53. Witz IP, Ran M (1992) FcR may function as a progression factor of nonlymphoid tumors. Immunol Res 11:283-295
54. Azeredo da Silveira S, Kikuchi S, Fossati-Jimack L, Moll T, Saito T, Verbeek JS, Botto M, Walport MJ, Carroll M, Izui S (2002) Complement activation selectively potentiates the pathogenicity of the IgG2b and IgG3 isotypes of a high affinity anti-erythrocyte autoantibody. J Exp Med 195:665-672
55. Camilleri-Broet S, Cassard L, Broet P, Delmer A, Le Touneau A, Diebold J, Fridman WH, Molina TJ, Sautes-Fridman C (2004) FcgammaRIIB is differentially expressed during B cell maturation and in B-cell lymphomas. Br J Haematol 124:55-62
56. Rao SP, Vora KA, Manser T (2002) Differential expression of the inhibitory IgG Fc receptor FcgammaRIIB on germinal center cells: implications for selection of high-affinity B cells. J Immunol 169:1859-1868
57. Pulford K, Ralfkiaer E, MacDonald SM, Erber WN, Falini B, Gatter KC, Mason DY (1986) A new monoclonal antibody (KB61) recognizing a novel antigen which is selectively expressed on a subpopulation of human B lymphocytes. Immunology 57:71-76
58. Macardle PJ, Mardell C, Bailey S, Wheatland L, Ho A, Jessup C, Roberton DM, Zola H (2002) FcgammaRIIb expression on human germinal center B lymphocytes. Eur J Immunol 32:3736-3744
59. Pearse RN, Kawabe T, Bolland S, Guinamard R, Kurosaki T, Ravetch JV (1999) SHIP recruitment attenuates Fc gamma RIIB-induced B cell apoptosis. Immunity 10:753-760
60. Itoyama T, Nanjungud G, Chen W, Dyomin VG, Teruya-Feldstein J, Jhanwar SC, Zelenetz AD, Chaganti RS (2002) Molecular cytogenetic analysis of genomic instability at the 1q12-22 chromosomal site in B-cell non-Hodgkin lymphoma. Genes Chromosomes Cancer 35:318-328
61. Callanan MB, Le Baccon P, Mossuz P, Duley S, Bastard C, Hamoudi R, Dyer MJ, Klobeck G, Rimokh R, Sotto JJ, Leroux D (2000) The IgG Fc receptor, FcgammaRIIB, is a target for deregulation by chromosomal translocation in malignant lymphoma. Proc Natl Acad Sci U S A 97:309-314
62. Chen W, Palanisamy N, Schmidt H, Teruya-Feldstein J, Jhanwar SC, Zelenetz AD, Houldsworth J, Chaganti RS (2001) Deregulation of FCGR2B expression by 1q21 rearrangements in follicular lymphomas. Oncogene 20:7686-7693
63. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson Jr J, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511
64. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242
65. Camilleri-Broet S, Mounier N, Delmer A, Briere J, Casasnovas O, Cassard L, Gaulard P, Christian B, Coiffier B, Sautes-Fridman C (2004) FcgammaRIIB expression in diffuse large B-cell lymphomas does not alter the response to CHOP+rituximab (R-CHOP). Leukemia 18:2038-2040
66. Rankin CT, Veri MC, Gorlatov S, Tuaillon N, Burke S, Huang L, Inzunza HD, Li H, Thomas S, Johnson S, Stavenhagen J, Koenig S, Bonvini E (2006) CD32B, the human inhibitory Fc-gamma receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma. Blood 108:2384-2391
67. Tartour E, de La Salle H, de La Salle C, Teillaud C, Camoin L, Galinha A, Latour S, Hanau D, Fridman WH, Sautes C (1993) Identification, in mouse macrophages and serum, of a soluble receptor for the Fc portion of IgG (Fc>=R) encoded by an alternatively spliced transcript of the Fc>=RII gene. Intern Immunol 5:859-868
68. Fridman WH, Teillaud JL, Bouchard C, Teillaud C, Astier A, Tartour E, Galon J, Mathiot C, Sautes C (1993) Soluble Fc gamma receptors. J Leukoc Biol 54:504-512
69. Astier A, de la Salle H, de la Salle C, Bieber T, Esposito-Farese ME, Freund M, Cazenave JP, Fridman WH, Teillaud JL, Hanau D (1994) Human epidermal Langerhans cells secrete a soluble receptor for IgG (Fc gamma RII/CD32) that inhibits the binding of immune complexes to Fc gamma R+ cells. J Immunol 152:201-212
70. Astier A, Merle-Beral H, de la Salle H, Moncuit J, Cazenave JP, Fridman WH, Hanau D, Teillaud JL (1997) Soluble Fcgamma receptor, Fc gammaRIIa2, is present in two forms in human serum and is increased in patients: with stage C chronic lymphocytic leukemia. Leuk Lymphoma 26:317-326
71. Galon J, Moldovan I, Galinha A, Provost-Marloie MA, Kaudewitz H, Roman-Roman S, Fridman WH, Sautes C (1998) Identification of the cleavage site involved in production of plasma soluble Fc gamma receptor type III (CD16). Eur J Immunol 28:2101-2107
72. Wines BD, Gavin A, Powell MS, Steinitz M, Buchanan RR, Mark Hogarth P (2003) Soluble FcgammaRIIa inhibits rheumatoid factor binding to immune complexes. Immunology 109:246-254
73. Enyedy EJ, Mitchell JP, Nambiar MP, Tsokos GC (2001) Defective FcgammaRIIb1 signaling contributes to enhanced calcium response in B cells from patients with systemic lupus erythematosus. Clin Immunol 101:130-135
74. Oka T, Ouchida M, Koyama M, Ogama Y, Takada S, Nakatani Y, Tanaka T, Yoshino T, Hayashi K, Ohara N, Kondo E, Takahashi K, Tsuchiyama J, Tanimoto M, Shimizu K, Akagi T (2002) Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. Cancer Res 62:6390-6394